Is reduced ornithine-δ-aminotransferase activity the cause of vigabatrin-associated visual field defects?

Epilepsy Research

Volumn 92, Issue 1, 2010, Pages 48-53

  Sorri, Iiris ^a   Brigell, Mitchell G ^b   Mályusz, Miklos ^c   Mahlamäki, Eija ^a   de Meynard, Capucine ^d   Kälviäinen, Reetta ^a  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^c UNIVERSITY OF KIEL   (Germany)

^d PFIZER INC   (United States)

Author keywords

AED; Gyrate atrophy; OAT; Study funded by Pfizer, Inc; Vigabatrin; Visual fields

Indexed keywords

4 AMINOBUTYRATE AMINOTRANSFERASE; 4 AMINOBUTYRIC ACID; GLUTAMIC ACID; GLUTAMINE; LYSINE; ORNITHINE; ORNITHINE OXOACID AMINOTRANSFERASE; TIAGABINE; VIGABATRIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ASSAY; EPILEPSY; HUMAN; LYMPHOCYTE; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; RETINA DISEASE; RETINA GYRATE ATROPHY; THROMBOCYTE; TONOMETRY; TREATMENT DURATION; VISUAL FIELD DEFECT; VISUAL SYSTEM EXAMINATION;

4-AMINOBUTYRATE TRANSAMINASE; ADOLESCENT; ADULT; AGED; ANTICONVULSANTS; EPILEPSY; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; LYMPHOCYTES; MALE; MIDDLE AGED; ORNITHINE-OXO-ACID TRANSAMINASE; PERCEPTUAL DISORDERS; VIGABATRIN; VISUAL FIELD TESTS; VISUAL FIELDS; YOUNG ADULT;

EID: 77957881921     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2010.08.006     Document Type: Article

References (28)

1. Butler W.H., Ford G.P., Newberne J.W. A study of the effects of vigabatrin on the central nervous system and retina of Sprague-Dawly and Lister-Hooded rats. Toxicol. Pathol. 1987, 15:143-148.
2. Daune G., Seiler N. Interrelationships between ornithine, glutamate, and GABA II. Consequences of inhibition of GABA-T and ornithine aminotransferase in brain. Neurochem. Res. 1988, 13:69-75.
3. Foletti G.B., Delisle M.C., Bachmann C. Reduction of plasma alanine aminotransferase during vigabatrin treatment. Epilepsia 1995, 36:804-809.
4. Frisén L., Malmgren K. Characterization of vigabatrin-associated optic atrophy. Acta Ophthalmol. Scand. 2003, 81:466-473.
5. Hayasaka S., Saito T., Nakajima H., Takahashi O., Mizuno K., Tada K. Clinical trials of vitamin B6 and proline supplementation for gyrate atrophy of the choroid and retina. Br. J. Ophthalmol. 1985, 69:283-290.
6. Heinänen K., Näntö-Salonen K., Leino L., Pulkki K., Heinonen O., Valle D., Simell O. Gyrate atrophy of the choroid and retina: lymphocyte ornithine-δ-aminotransferase activity in different mutations and carriers. Pediatr. Res. 1998, 44:381-385.
7. Hisama F., Sattson R., Lee H., Felice K., Petroff O. GABA and the ornithine δ-aminotransferase gene in vigabatrin-associated visual field defects. Seizure 2001, 10:505-507.
8. Izumi Y., Ishikawa M., Benz A.M., Izume M., Zorumski C.F., Thio L.L. Acute vigabatrin retinotoxicity in albino rats depends on light but not GABA. Epilepsia 2004, 45:1043-1048.
9. Jammoul F., Wang Q., Nabbour R., et al. Taurine deficiency is a cause of vigabatrin-induced retinal phototoxicity. Ann. Neurol. 2009, 65:98-107.
10. Jammoul F, Deógardin J, Pain D. Taurine deficiency damages photoreceptors and retinal ganglion cells in vigabatrin-treated neonatal rats. Mol. Cell. Neurosci. 2010, 43:414-421.
11. Kaiser-Kupfer M.I., Caruso R.C., Valle D., Reed G.F. Use of an arginine-restricted diet to slow progression of visual loss in patients with gyrate atrophy. Arch. Ophthalmol. 2004, 122:982-984.
12. Kälviäinen R, Nousiainen I, Mäntyjärvi M, Nikoskelainen E, Partanen J, Partanen K, Riekkinen P Sr. Vigabatrin A gabaergic antiepileptic drug, causes concentric visual field defects. Neurology 1999, 53:922-926.
13. Kaneko S., Ando A., Okuda-Ashitaka E., Maeda M., Furuta K., Suzuki M., Matsumura M., Ito S. Ornithine transport via cationic amino acid transporter-1 is involved in ornithine cytotoxicity in retina pigment epithelial cells. Invest. Ophthalmol. Vis. Sci. 2007, 48:464-471.
14. Krauss G.L., Johnson M.A., Miller N.R. Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings. Neurology 1998, 50:614-618.
15. Lamba J.K., Lin Y.S., Schuetz E.G., Thummel K.E. Genetic contribution to variable human CYP3A-mediated metabolism. Adv. Drug Deliv. Rev. 2002, 54:1271-1294.
16. Nousiainen I., Mäntyjärvi M., Kälviäinen R. Visual function in patients treated with the GABAergic anticonvulsant drug tiagabine. Clin. Drug Invest. 2000, 20(6):393-400.
17. Ohkubo Y., Ueta A., Ito T., Sumi S., Yamada M., Ozawa K., Togari H. Vitamin B6-responsive ornithine aminotransferase deficiency with a novel mutation G237D. Tohoku J. Exp. Med. 2005, 205:335-342.
18. Peltola K., Näntö-Salonen K., Heinonen O., Jääskeläinen S., Heinänen K., Simell O., Nikoskelainen E. Ophthalmologic heterogeneity in subjects with gyrate atrophy of choroid and retina harboring the L402P mutation of ornithine aminotransferase. Ophthalmology 2001, 108:721-729.
19. Roubertie A., Bellet H., Echenne B. Vigabatrin-associated retinal cone dysfunction. Neurology 1998, 51:1779. Letter to the editor.
20. Schechter P.J., Tranier Y., Jung M.J., Böhlen P. Audiogenic seizure protection by elevated brain GABA concentration in mice: effects of gamma-acetylenic GABA and gamma-vinyl GABA, two irreversible GABA-T inhibitors. Eur. J. Pharmacol. 1977, 45:319-328.
21. Sills G.J., Patsalos P.N., Butler E., Forrest G., Ratnaraj N., Brodie M.J. Visual field constriction accumulation of vigabatrin but not tiagabine in the retina. Neurology 2001, 57:196-200.
22. Suzdak P.D., Jansen J.A. A review of the preclinical pharmacology of tiagabine: a potent and selective anticonvulsant GABA uptake inhibitor. Epilepsia 1995, 36:612-626.
23. Takki K., Simell O. Genetic aspects in gyrate atrophy of the choroid and retina with hyperornithinemia. Br. J. Ophthalmol. 1974, 58:907-916.
24. Tomi M., Kitade N., Hirose S., Yokota N., Akanuma S., Tachikawa M., Hosoya K. Cationic amino acid transporter 1-ediated l-arginine transport at the inner blood-retina barrier. J. Neurochem. 2009, 111:716-725.
25. Ueda M., Masu Y., Ando A., Maeda H., Del Monte M.A., Uyama M., Ito S. Prevention of ornithine cytotoxicity by proline in human retinal pigment epithelial cells. Invest. Ophthalmol. Vis. Sci. 1998, 39:820-827.
26. Wang T., Steel G., Milam A.H., Valle D. Correction of ornithine accumulation prevents retinal degeneration in a mouse model of gyrate atrophy of the choroid and retina. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:1224-1229.
27. Wild J.M., Martinez C., Reinshagen G., Harding G.F.A. Characteristics of a unique visual field defect attributed to vigabatrin. Epilepsia 1999, 40:1784-1794.
28. Yoneda Y., Roberts E., Dietz G.W. A new synaptosomal biosynthetic pathway of glutamate and GABA from ornithine and its negative feedback inhibition by GABA. J. Neurochem. 1982, 381686-381694.